The consequences of HIV infection and antiretroviral therapy use for cardiovascular disease risk: shifting paradigms.
about
Incomplete immune recovery in HIV infection: mechanisms, relevance for clinical care, and possible solutionsHigh-density lipoprotein particles and markers of inflammation and thrombotic activity in patients with untreated HIV infection.Recent key advances in human immunodeficiency virus medicine and implications for ChinaEffects of ezetimibe on cholesterol metabolism in HIV-infected patients with protease inhibitor-associated dyslipidemia: a single-arm intervention trialBiomarkers and HIV-associated cardiovascular disease.Retinal arterioles narrow with increasing duration of anti-retroviral therapy in HIV infection: a novel estimator of vascular risk in HIV?Development of diagnostic criteria for serious non-AIDS events in HIV clinical trials.Lymphoid fibrosis occurs in long-term nonprogressors and persists with antiretroviral therapy but may be reversible with curative interventions.Inflammation predicts changes in high-density lipoprotein particles and apolipoprotein A1 following initiation of antiretroviral therapy.18FDG PET-CT imaging detects arterial inflammation and early atherosclerosis in HIV-infected adults with cardiovascular disease risk factorsEffect of Chocolate and Yerba Mate Phenolic Compounds on Inflammatory and Oxidative Biomarkers in HIV/AIDS IndividualsInflammatory biomarker changes and their correlation with Framingham cardiovascular risk and lipid changes in antiretroviral-naive HIV-infected patients treated for 144 weeks with abacavir/lamivudine/atazanavir with or without ritonavir in ARIES.Considerations for Endpoint Selection When Designing HIV Clinical Trials.Accelerated aging and human immunodeficiency virus infection: emerging challenges of growing older in the era of successful antiretroviral therapy.
P2860
Q27021524-60A814D4-2FA9-46C3-A935-80E8B54A3446Q33556997-50C75DB4-6FC0-4B4C-8F26-7013D884330CQ33933502-129A4816-10ED-4115-8010-BDD4B2C50D77Q34217293-7C632B6E-08F9-488D-BEEF-7F0CC6E9B12FQ34335486-1C63EF33-70FF-484B-B757-DF48B8A567EDQ34516572-9CDBF479-2686-4160-989B-193D49E66CE0Q35030752-EA21300C-9E52-4826-9202-E9D99E4715B6Q35558823-87ADBE69-1128-4C66-A487-1EEF3DAAA0BCQ35873877-7B311243-C2A5-4883-BF86-A10DFC61A8E9Q36311889-CBA5335E-8406-44C7-B6EF-0B6378269891Q36941675-52E453DA-3A90-4306-B250-3E67BA7C6946Q36974022-23E6D77D-76E7-416C-BFC5-DAA8989D9079Q37967498-062D2879-A8E0-4C17-8408-79B52C974DE6Q37972113-1E46F34D-F68D-4832-AB23-3E83B6D18069
P2860
The consequences of HIV infection and antiretroviral therapy use for cardiovascular disease risk: shifting paradigms.
description
2009 nî lūn-bûn
@nan
2009 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
The consequences of HIV infect ...... ease risk: shifting paradigms.
@ast
The consequences of HIV infect ...... ease risk: shifting paradigms.
@en
type
label
The consequences of HIV infect ...... ease risk: shifting paradigms.
@ast
The consequences of HIV infect ...... ease risk: shifting paradigms.
@en
prefLabel
The consequences of HIV infect ...... ease risk: shifting paradigms.
@ast
The consequences of HIV infect ...... ease risk: shifting paradigms.
@en
P2093
P2860
P1476
The consequences of HIV infect ...... ease risk: shifting paradigms.
@en
P2093
James D Neaton
Jason V Baker
W Keith Henry
P2860
P304
P356
10.1097/COH.0B013E328329C62F
P577
2009-05-01T00:00:00Z